Topics

AbbVie buying Allergan in $63B deal for its post-Humira future

03:40 EDT 25 Jun 2019 | BioPharmaDive

Unlike Bristol-Myers' takeover of Celgene, AbbVie's cash-and-stock offer for Allergan is not about R&D. "We're not betting on the pipeline," said AbbVie CEO Richard Gonzalez. 

Original Article: AbbVie buying Allergan in $63B deal for its post-Humira future

NEXT ARTICLE

More From BioPortfolio on "AbbVie buying Allergan in $63B deal for its post-Humira future"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...